While many Massachusetts companies officially opened their doors this week after temporarily closing over COVID-19 concerns, one Boston-area biotech company has developed a tool to keep workers safe as the pandemic persists. “I was thinking, ‘While we’re going to leave [the office], that means at some point we’re going to come back. How does that work?’” […]

Officials with the FDA have granted Fast Track designation to Cardiff Oncology’s onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). Fast Track designation is intended to facilitate development and expedite review of drugs to address an unmet medical need in the […]

Cardiff Oncology, Inc., a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to onvansertib, its oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, […]